View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 25, 2017

Halozyme begins PEGPH20 dosing in Phase Ib/II trial for gastric cancer

Halozyme Therapeutics has started dosing patients with gastric cancer in a Phase Ib/II clinical trial of its investigational new drug PEGPH20 combined with atezolizumab (Tecentriq).

Halozyme Therapeutics has started dosing patients with gastric cancer in a Phase Ib/II clinical trial of its investigational new drug PEGPH20 combined with atezolizumab (Tecentriq).

PEGPH20 is a PEGylated form of the firm’s recombinant human hyaluronidase, while atezolizumab is Genentech’s anti-PDL1 cancer immunotherapy.

Being developed as an enzyme, PEGPH20 could temporarily degrade HA component in the tumour microenvironment that might constrict blood vessels upon accumulation.

The degradation is expected to result in decreased tumour pressure and increased blood flow to enable better access for chemotherapies and immunotherapies.

The open-label, multi-centre, randomised Phase Ib/II trial will investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of the combination in subjects with previously treated locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.

To be conducted in the US and additional international markets, the trial includes a retrospective analysis of the HA-high population detected through Ventana HA companion diagnostic assay.

“Our hope is to advance new treatment options for patients with each ongoing study.”

Halozyme Therapeutics president and CEO Dr Helen Torley said: “PEGPH20 is currently under evaluation in six indications with potential across a range of difficult to treat solid tumours.

“Our hope is to advance new treatment options for patients with each ongoing study.”

The Phase Ib/II trial is part of the firm’s clinical collaboration agreement formed last year with Genentech to study the PEGPH20 and atezolizumab combination for up to eight different types of tumour.

Under the collaboration, the combination will be evaluated on Roche’s Phase Ib/II cancer immunotherapy development platform, MORPHEUS, designed for the development of rapid and efficient cancer immunotherapy combinations.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena